Daewoong Investment

Daewoong Investment is the wholly owned corporate venture capital subsidiary of the Daewoong Group, a Korean healthcare conglomerate anchored by Daewoong Pharmaceutical. The investment team accesses deal flow through the parent's R&D and business development networks, and its investment thesis is built around therapies that can leverage the group's manufacturing and domestic distribution infrastructure.

Yoon Jae-seung is the Chief Executive Officer of Daewoong Investment and a senior figure within the broader Daewoong Group. He oversees the investment committee's strategic direction, ensuring alignment between venture portfolio construction and the parent company's therapeutic pipeline priorities.

Daewoong Investment typically participates as a co-investor or syndicate partner rather than a lead investor, leaving lead roles to specialist life sciences VCs. The firm may take observer rights or board seats when a portfolio company has active co-development or licensing discussions with Daewoong's operating divisions.

The firm invests primarily in South Korea, the United States, and select European biotech clusters. Its geographic mandate follows the parent company's outward-looking partnership and licensing strategy, with particular interest in assets that can be bridged into Asian clinical trials and regulatory approvals.

Daewoong Investment makes both direct equity investments into portfolio companies and selective fund commitments to external venture capital managers. The fund commitments function as a sourcing antenna for early exposure to therapeutic assets that could later become strategic partners or acquisition targets for the parent.